SCIENCE BRIEFS.
Informing Ontario’s response to COVID-19
Science Brief Categories
- Epidemiology, Public Health & Implementation
- Health Equity & Social Determinants of Health
- Infectious Diseases & Clinical Care
- Public Policy & Economic Impact
Epidemiology, Public Health & Implementation
-
Fighting COVID-19 in Ontario: The Way Forward
-
Update on COVID-19 Projections
-
Update on COVID-19 Projections
-
COVID-19 Hospitalizations, ICU Admissions and Deaths Associated with the New Variants of Concern
-
Routine Asymptomatic SARS-CoV-2 Screen Testing of Ontario Long-Term Care Staff After COVID-19 Vaccination
Health Equity & Social Determinants of Health
-
Mobile In-Home COVID-19 Vaccination of Ontario Homebound Older Adults by Neighbourhood Risk
-
Mobile On-Site COVID-19 Vaccination of Naturally Occurring Retirement Communities by Neighbourhood Risk in Toronto
-
A Strategy for the Mass Distribution of COVID-19 Vaccines in Ontario Based on Age and Neighbourhood
Infectious Diseases & Clinical Care
-
Strategies to Manage Tocilizumab Supply During the COVID-19 Pandemic
-
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19
-
Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) following AstraZeneca COVID-19 Vaccination: Interim Guidance for Healthcare Professionals in Emergency Department and Inpatient Settings
-
Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) following AstraZeneca COVID-19 Vaccination: Interim Guidance for Healthcare Professionals in the Outpatient Setting
-
Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) Following AstraZeneca COVID-19 Vaccination: Lay Summary
Public Policy & Economic Impact
Science Briefs coming soon.